Evolus Inc. (EOLS)
| Bid | 9.31 |
| Market Cap | 654.63M |
| Revenue (ttm) | 266.27M |
| Net Income (ttm) | -50.42M |
| EPS (ttm) | -0.81 |
| PE Ratio (ttm) | -12.71 |
| Forward PE | 656.67 |
| Analyst | Buy |
| Ask | 12.28 |
| Volume | 1,416,232 |
| Avg. Volume (20D) | 860,136 |
| Open | 9.84 |
| Previous Close | 9.54 |
| Day's Range | 9.46 - 10.51 |
| 52-Week Range | 8.67 - 17.82 |
| Beta | 0.97 |
About EOLS
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California....
Analyst Forecast
According to 4 analyst ratings, the average rating for EOLS stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 142.84% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · businesswire.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763...
1 month ago · businesswire.com
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
